According to our recent payer coverage analysis for hereditary angioedema treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.
To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.
Payer Coverage: A complex mix of pharmacy and medical benefit coverage exists for HAE treatments. Products are generally covered with a PA and there are minimal step restrictions, with the exception of one or two treatments. Over the past quarter, restrictions increased across all channels for payer pharmacy benefit formularies.
Source: MMIT data as of Q1 2018
Trends: Recent news related to HAE treatments highlights some key trends in this therapeutic area. Recent legislation could end charitable premium and co-pay assistance programs for HAE patients across the nation. Patient advocacy groups and associations like HAEA are doing whatever they can to position against this action.
To read the full Reality Check on hereditary angioedema with key findings on clinical characteristics, HAE drug market access and payer coverage, please click on the button below: